Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points 1400 days (3.85 years) post randomization [clinicaltrials_resource:baa5e69382f1e274471c06e449c07090]
Peg-interferon alfa-2a 90 mcg/week
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points 1400 days (3.85 years) post randomization [clinicaltrials_resource:baa5e69382f1e274471c06e449c07090]
Peg-interferon alfa-2a 90 mcg/week
Bio2RDF identifier
baa5e69382f1e274471c06e449c07090
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:baa5e69382f1e274471c06e449c07090
measure [clinicaltrials_vocabulary:measure]
Progression of Liver Disease a ...... osis Score of 2 or More Points
time frame [clinicaltrials_vocabulary:time-frame]
1400 days (3.85 years) post randomization
description
Peg-interferon alfa-2a 90 mcg/week
identifier
clinicaltrials_resource:baa5e69382f1e274471c06e449c07090
title
Progression of Liver Disease a ...... 3.85 years) post randomization
@en
type
label
Progression of Liver Disease a ...... 5e69382f1e274471c06e449c07090]
@en